Stock report · Delisted · Nasdaq
Durect Corporation (DRRX)
1.91USD Delisted Final close · Sep 10, 2025
DRRX no longer trades. Durect was delisted from the Nasdaq in September 2025.
All prices on this page are historical. The last trade was on September 10, 2025, at $1.91.
DRRX stock price history
Final trading statistics
- Final close
- $1.91
- Final trading day
- Sep 10, 2025
- Market cap at delisting
- $59.31M
- Shares outstanding
- 31.05M
- Final 52-week range
- $0.48 – $2.64
- Avg. volume (final 3 mo.)
- 1,193,413
- All-time high
- $158.12 · Nov 2000
- All-time low
- $0.50 · May 2025
- Return since IPO
- -98.7%
- Beta
- 0.93
- Book value / share
- $0.11
- Price / book
- 17.05
About Durect Corporation
DURECT Corporation was a biopharmaceutical company built around an epigenetic regulator program. Its lead candidate, larsucosterol, was an oral small molecule involved in lipid metabolism, stress and inflammation, and cell survival, studied for alcohol-associated hepatitis and metabolic dysfunction-associated steatohepatitis.
Its products included POSIMIR, which releases bupivacaine over three days for post-surgical pain in adults; PERSERIS, an injectable for schizophrenia in adults; and Methydur for ADHD. It had agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited.
Incorporated in 1998 and based in Cupertino, California, it became a subsidiary of Bausch Health Americas, Inc. as of September 11, 2025. Its stock was delisted from the Nasdaq that month, with the last trade on September 10, 2025 at $1.91.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Cupertino, CA
- Employees
- 13
- IPO date
- September 28, 2000
- Delisted
- September 10, 2025
- SEC CIK
- 1082038
Durect financials before the delisting
The last 5 fiscal years Durect reported as a public company, fiscal year ending December.
DRRX revenue and net income
DRRX earnings per share
DRRX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $2.03M | −$8.3M | −$0.57 |
| FY2023 | $8.55M | −$27.6M | −$1.13 |
| FY2022 | $19.28M | −$35.3M | −$1.56 |
| FY2021 | $13.98M | −$36.3M | −$1.60 |
| FY2020 | $30.11M | −$13.4M | −$0.70 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Durect stock FAQ
What happened to Durect stock?
Durect was delisted from the Nasdaq in September 2025. The final close was $1.91 on September 10, 2025.
Can I still buy DRRX stock?
No. DRRX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on September 10, 2025.
What was the last price of DRRX?
DRRX last closed at $1.91 on September 10, 2025, which valued the company at about $59.31M.
How did Durect do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Durect reported revenue of $2.03M and net income of −$8.3M.
When did Durect go public?
Durect shares started trading on September 28, 2000.
DRRX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.